サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1642839

経口タンパク質とペプチドの市場規模、シェア、動向、予測：薬剤タイプ、用途、地域別、2025年～2033年

Oral Proteins and Peptides Market Size, Share, Trends, and Forecast by Drug Type, Applications, and Region, 2025-2033

出版日
発行
IMARC
ページ情報
英文 138 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
経口タンパク質とペプチドの市場規模、シェア、動向、予測：薬剤タイプ、用途、地域別、2025年～2033年
出版日: 2025年01月18日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

経口タンパク質とペプチドの世界市場規模は、2024年に18億米ドルとなりました。今後、IMARC Groupは、市場は2033年までに34億米ドルに達し、2025年から2033年にかけて7.13％のCAGRを示すと予測しています。現在、北米が市場を独占しており、2024年の市場シェアは97.8%を超えます。ドラッグデリバリー技術の進歩と非侵襲的治療に対する需要の高まりにより、市場は拡大しています。主な促進要因としては、糖尿病やがんなどの慢性疾患の有病率の増加と、イノベーションを促進するバイオテクノロジー企業と研究機関の継続的な協力関係が挙げられます。

タンパク質とペプチドは人体の天然成分であり、多くの生物学的プロセスにおいて重要な役割を果たしています。構造が複雑で胃や小腸で消化されやすいため、通常は注射で投与されます。しかし、経口タンパク質やペプチドは、ホルモン、胃、代謝障害を治療するために、経口経路から摂取することができます。このような課題を克服するために、分子を消化から守り、腸壁から血流に吸収されるような特殊な製剤が設計されています。これらの製剤には、腸溶性コーティング、ナノ粒子、その他のデリバリー技術が含まれます。経口タンパク質およびペプチドは、糖尿病、がん、自己免疫疾患など多くの慢性疾患の治療に広く利用されています。

経口タンパク質とペプチドの市場動向：

がん、糖尿病、心血管障害（CVDs）、後天性免疫不全症候群（AIDs）などの慢性疾患に罹患する患者の増加や、老人人口の増加が経口タンパク質とペプチドの市場の成長を促進する主な要因となっています。このほか、嗜好の変化や、大衆の間で効果的な経口薬や技術に対する需要が高まっていることも、市場の成長に寄与しています。さらに、消費者の健康意識の高まりや、経口タンパク質・ペプチドサプリメントの摂取に関連する数多くのメリットに対する意識の高まりが、市場に明るい展望をもたらしています。これに加えて、三次元（3D）プリンティング、ナノテクノロジー、遺伝子工学などの革新的な技術の進歩により、メーカーはより高度で費用対効果の高い製品バリエーションを製造できるようになり、これも重要な成長促進要因として作用しています。これと同時に、製薬企業間の広範な協力体制、ヘルスケア・インフラの大幅な進歩、研究開発（R&D）活動の活発化が、市場に有益な成長機会をもたらしています。さらに、消費者の可処分所得の増加、タンパク質が豊富な食生活の普及、プロテインパウダー、バー、シェイクの需要の急増、製品への容易なアクセスを提供するオンラインプラットフォームの普及が、市場の拡大を後押ししています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の経口タンパク質とペプチド市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • リナクロチド
    • 市場動向
    • 市場予測
  • プレカナチド
    • 市場動向
    • 市場予測
  • カルシトニン
    • 市場動向
    • 市場予測
  • インスリン
    • 市場動向
    • 市場予測
  • オクトレオチド
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • 胃および消化器疾患
    • 市場動向
    • 市場予測
  • 骨疾患
    • 市場動向
    • 市場予測
  • 糖尿病
    • 市場動向
    • 市場予測
  • ホルモン障害
    • 市場動向
    • 市場予測

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amryt Pharma Plc
    • AstraZeneca PLC
    • Biocon Limited
    • Novo Nordisk A/S
    • Oramed Ltd
    • Proxima Concepts Limited
図表

List of Figures

  • Figure 1: Global: Oral Proteins and Peptides Market: Major Drivers and Challenges
  • Figure 2: Global: Oral Proteins and Peptides Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Oral Proteins and Peptides Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Oral Proteins and Peptides Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Oral Proteins and Peptides Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Oral Proteins and Peptides Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Oral Proteins and Peptides (Linaclotide) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Oral Proteins and Peptides (Linaclotide) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Oral Proteins and Peptides (Plecanatide) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Oral Proteins and Peptides (Plecanatide) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Oral Proteins and Peptides (Calcitonin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Oral Proteins and Peptides (Calcitonin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Oral Proteins and Peptides (Insulin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Oral Proteins and Peptides (Insulin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Oral Proteins and Peptides (Octreotide) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Oral Proteins and Peptides (Octreotide) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Oral Proteins and Peptides (Gastric and Digestive Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Oral Proteins and Peptides (Gastric and Digestive Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Oral Proteins and Peptides (Bone Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Oral Proteins and Peptides (Bone Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Oral Proteins and Peptides (Diabetes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Oral Proteins and Peptides (Diabetes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Oral Proteins and Peptides (Hormonal Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Oral Proteins and Peptides (Hormonal Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: North America: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: North America: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: United States: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: United States: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Canada: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Canada: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Asia-Pacific: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Asia-Pacific: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: China: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: China: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Japan: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Japan: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: India: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: India: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: South Korea: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: South Korea: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Australia: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Australia: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Indonesia: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Indonesia: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Others: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Others: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Europe: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Europe: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Germany: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Germany: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: France: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: France: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: United Kingdom: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: United Kingdom: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Italy: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Italy: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Spain: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Spain: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Russia: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Russia: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Latin America: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Latin America: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Brazil: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Brazil: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Mexico: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Mexico: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Others: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Others: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Middle East and Africa: Oral Proteins and Peptides Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Middle East and Africa: Oral Proteins and Peptides Market: Breakup by Country (in %), 2024
  • Figure 73: Middle East and Africa: Oral Proteins and Peptides Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Global: Oral Proteins and Peptides Industry: Drivers, Restraints, and Opportunities
  • Figure 75: Global: Oral Proteins and Peptides Industry: Value Chain Analysis
  • Figure 76: Global: Oral Proteins and Peptides Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Oral Proteins and Peptides Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Oral Proteins and Peptides Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 3: Global: Oral Proteins and Peptides Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Oral Proteins and Peptides Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Oral Proteins and Peptides Market: Competitive Structure
  • Table 6: Global: Oral Proteins and Peptides Market: Key Players
目次
Product Code: SR112025A7530

The global oral proteins and peptides market size was valued at USD 1.8 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 3.4 Billion by 2033, exhibiting a CAGR of 7.13% from 2025-2033. North America currently dominates the market, holding a market share of over 97.8% in 2024. The market is growing due to advancements in drug delivery technologies and the rising demand for non-invasive treatments. Key drivers include the increasing prevalence of chronic diseases like diabetes and cancer coupled with ongoing collaborations between biotech firms and research institutions fostering innovation.

Proteins and peptides are natural components of the human body and play essential roles in many biological processes. Due to their complex structure and susceptibility to digestion in the stomach and small intestine, they are usually administered through injections. However, oral proteins and peptides can be taken via the oral path to treat hormonal, gastric, and metabolic disorders. They are designed to overcome these challenges by using specialized formulations that protect the molecules from digestion and allow them to be absorbed through the intestinal wall into the bloodstream. These formulations include enteric coatings, nanoparticles, and other delivery technologies. Oral proteins and peptides are extensively utilized to treat numerous chronic diseases, such as diabetes, cancer, and autoimmune disorders.

Oral Proteins and Peptides Market Trends:

The increasing volume of patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular disorders (CVDs), and acquired immunodeficiency syndrome (AIDs), and the expanding geriatric population represent the key factors driving the oral proteins and peptides market growth. Besides this, shifting preferences and the rising demand for effective oral drugs and technology among the masses are contributing to the market growth. Moreover, the escalating consumer health consciousness and the growing awareness of the numerous benefits associated with the consumption of oral protein and peptide supplements are creating a positive outlook for the market. In addition to this, innovative technological advancements, such as three-dimensional (3D) printing, nanotechnology, and genetic engineering, have enabled manufacturers to produce more advanced and cost-effective product variants, which is acting as another significant growth-inducing factor. Concurrent with this, the extensive collaborative efforts between pharmaceutical companies, significant advancements in the healthcare infrastructure, and rising research and development (R&D) activities are presenting remunerative growth opportunities for the market. Furthermore, the inflating disposable income of consumers, the widespread adoption of protein-rich diets, the surging demand for protein powder, bars, and shakes, and the increasing proliferation of online platforms providing easy product access are aiding in market expansion.

Oral Proteins and Peptides Industry Segmentation:

Drug Type Insights:

  • Linaclotide
  • Plecanatide
  • Calcitonin
  • Insulin
  • Octreotide

Application Insights:

  • Gastric and Digestive Disorders
  • Bone Diseases
  • Diabetes
  • Hormonal Disorders

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for oral proteins and peptides. Some of the factors driving the North America oral proteins and peptides market included the increasing prevalence of chronic diseases, the shifting consumer preference for oral drugs, and innovative product advancements.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global oral proteins and peptides market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1.How big is the oral proteins and peptides market?
  • 2.What is the future outlook of oral proteins and peptides market?
  • 3.What are the key factors driving the oral proteins and peptides market?
  • 4.Which region accounts for the largest oral proteins and peptides market share?
  • 5.Which are the leading companies in the global oral proteins and peptides market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oral Proteins and Peptides Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Linaclotide
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Plecanatide
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Calcitonin
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Insulin
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Octreotide
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Gastric and Digestive Disorders
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Bone Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Diabetes
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Hormonal Disorders
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

  • 9.1 Overview
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amryt Pharma Plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Biocon Limited
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Novo Nordisk A/S
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Oramed Ltd
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Proxima Concepts Limited
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.